Wipfli Financial Advisors’s Supernus Pharmaceuticals SUPN Stock Holding History

Wipfli Financial Advisors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$5K	Buy	+150	New	+$4.88K	﹤0.01%	2097

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wipfli Financial Advisors's SUPN Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Supernus Pharmaceuticals (SUPN) in Q3 2022: 150 shares worth $5K. The stake represents ﹤0.01% of the portfolio and ranks #2097 among its holdings.

244 funds tracked by Wall St. Rank hold SUPN as of Q3 2022.

Wipfli Financial Advisors held 150 shares of Supernus Pharmaceuticals worth $5K as of Q3 2022.
Supernus Pharmaceuticals was a new Wipfli Financial Advisors position in Q3 2022.
Supernus Pharmaceuticals made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2097 holding.
244 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.